Influence of rifampicin pretreatment on the pharmacokinetics of celecoxib in healthy male volunteers

Drug Metabolism and Drug Interactions

Volumn 19, Issue 4, 2003, Pages 287-295

  Jayasagar, G ^a   Krishna Kumar, M ^a   Chandrasekhar, K ^a   Madhusudan Rao, Y ^a  

^a KAKATIYA UNIVERSITY   (India)

Author keywords

Celecoxib; CYP2C9; Pharmacokinetics; Rifampicin

Indexed keywords

CELECOXIB; R CIN 600; REVEBRA 200; RIFAMPICIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BONE INFECTION; COMPUTER PROGRAM; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG METABOLISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; INFECTIOUS ARTHRITIS; LEPROSY; LONG TERM CARE; MALE; NORMAL HUMAN; TUBERCULOSIS; VOLUNTEER;

EID: 1642528442     PISSN: 07925077     EISSN: None     Source Type: Journal    
DOI: 10.1515/DMDI.2003.19.4.287     Document Type: Article

References (15)

1. Simon LS, Lanza FL, Lipsky PE, et al. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase-2 inhibitor. Arthritis Rheum 1998; 41: 1501-1602.
2. Hubbard RC, Koepp RJ, Yu S, et al. SC-58635 (celecoxib), a novel COX2 selective inhibitor, is effective as a treatment for osteoarthritis (OA) in a short-term pilot study. Arthritis Rheum 1996; 39 (Suppl): S226 (Abst 1188).
3. Karim A, Tolbert D, Hunt TL, et al. Celecoxib, a specific COX-2 inhibitor, has no significant effect on methotrexate pharmacokinetics in patients with rheumatoid arthritis. J Rheumatol 1999; 26: 2539-2543.
4. Food and Drug Administration. New drug application #20998: Clinical pharmacology/biopharmaceutics review section celecoxib. Bethesda, MD: FDA, 1998.
5. Vesely JJ, Pien FD, Pien BC. Rifampicin, a useful drug for nonmycobacterial infections. Pharmacotherapy 1998; 18: 345-357.
6. Venkatesan K. Pharmacokinetic drug interactions with rifampicin. Clin Pharmacokinet 1992; 22: 47-65.
7. Heimark LD, Gibaldi M, Trager WF, O'Reilly RA, Goulart DA. The mechanism of the warfarin-rifampicin drug interaction in humans. Clin Pharmacol Ther 1987; 42: 388-394.
8. Dilger K, Hoffman U, Klotz U. Enzyme induction in the elderly: effect of rifampin on the pharmacokinetics and pharmacodynamics of propafenone. Clin Pharmacol Ther 2000; 67: 512-520.
9. Branch RA, Adedoyin A, Frye RF, Wilson JW, Romkes M. In vivo modulation of CYP enzymes by quinidine and rifampin. Clin Pharmacol Ther 2000; 68: 401-411.
10. Syvalahu E, Pihlajamaki K, Iisalo E. Effect of tuberculostatic agents on the response of serum growth hormone and immunoreactive insulin to intravenous tolbutamide, and on the half life of tolbutamide. Int J Clin Pharmacol Biopharm 1976; 13: 83-89.
11. Niemi M, Backman JT, Neuvonen M, Neuvonen PJ, Kvisto KT. Effects of rifampin on the pharmacokinetics and pharmacodynamics of glyburide and glipizide. Clin Pharmacol Ther 2001; 69: 400-406.
12. Alapati VR, Chaluvadi MR, Krishna DR. Influence of rifampicin pretreatment on the pharmacokinetics of tinidazole in healthy male volunteers. Clin Pharmacokinet 2001; 21: 783-787.
13. Schuetz EG, Beck WT, Schuetz JD. Modulators and substrates of P-gp and cytochrome P450 3A coordinately upregulate these proteins in human colon carcinoma cells. Mol Pharmacol 1996; 49: 311-318.
14. Jayasagar G, Krishna Kumar M, Chandrasekhar K, Siva Prasad P, Madhusudan Rao Y. Validated HPLC method for the determination of celecoxib in human serum and its application in a clinical pharmacokinetic study. Pharmazie 2002; 57: 619-621.
15. Davies NM, McLachlan AJ, Day RO, Williams KM. Clinical pharmacokinetics and pharmacodynamics of celecoxib. A selective cyclo-oxygenase-2 inhibitor. Clin Pharmacokinet 2000; 38: 225-242.